Interestingly, in addition to inhibiting the Nrf2 pathway, brusatol increased ROS generation in pancreatic cancer cells which is consistent with the effects of brusatol on 549 cells. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.